Displaying 132 (all) recruiting clinical trials.
-
A single arm phase II study of ADjuvant Endocrine therapy subcutaneous Pertuzumab and Trastuzumab fixed-dose combination for patients with anatomic stage I hormone receptor-positive HER2-positive breast cancer (ADEPT)
This is a single arm open-label phase II trial of adjuvant Fixed Dose Combination (FDC) of subcutaneous (SC) trastuzumab (H) plus pertuzumab (P) and endocrine ...Phase
Interventional
-
Phase 1 First-In-Human Study to Explore the Safety Tolerability and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors
The tumor-associated antigens mesothelin (MSLN) and cadherin-3 (CDH3) are co-expressed in multiple tumor types, with minimal overlap observed in normal tissues. AMG 305 is a ...Phase
Interventional
-
A Phase 2 Study of Futibatinib in Combination with PD-1 Antibody-based Standard of Care Therapy in Patients with Solid Tumors
A Phase 2 Study of Futibatinib in Combination with PD-1 Antibody-based Standard of Care Therapy in Patients with Solid TumorsPhase
Interventional
-
A PHASE II OPEN-LABEL MULTICENTER RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF ADJUVANT AUTOGENE CEVUMERAN PLUS ATEZOLIZUMAB AND MFOLFIRINOX VERSUS MFOLFIRINOX ALONE IN PATIENTS WITH RESECTED PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)
The purpose of this study is to evaluate the efficacy and safety of adjuvant autogene cevumeran plus atezolizumab and modified leucovorin, 5-fluorouracil (5-FU), irinotecan, and ...Phase
Interventional
-
A Master Protocol for the Multi-Cohort Phase 1/2 Study of DCC-3116 in Combination with Anticancer Therapies in Participants with Advanced Malignancies
This master protocol is a Phase 1/2, multicenter, open-label (unless otherwise specified in a combination-specific module) study of DCC-3116 in combination with anticancer therapies ...Phase
Interventional
-
A Phase II Study of the Interleukin-6 Receptor Inhibitor Sarilumab in Combination with Ipilimumab Nivolumab and Relatlimab in Patients with Unresectable Stage III or Stage IV Melanoma
A Phase II Study of the Interleukin-6 Receptor Inhibitor Sarilumab in Combination with Ipilimumab, Nivolumab and Relatlimab in Patients with Unresectable Stage III or Stage ...Phase
Interventional
-
A Randomized Open-label Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician s Choice in Patients with Triple Negative Breast Cancer That Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy
This is an international, multicenter, open-label, randomized, Phase 3 study in patients with TNBC who have received neoadjuvant chemotherapy with or without checkpoint inhibitor (CPI ...Phase
Interventional
-
A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients with Advanced NSCLC and Other Solid Tumors (ALKOVE-1)
A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients with Advanced NSCLC and Other Solid Tumors (ALKOVE-1)Phase
Interventional
-
A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination with Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients with Pancreatic Cancer
Single Arm Phase Ib study at fixed dose of standard of care chemotherapy and anti PD1 and IL1b to evaluate the safety and preliminary toxicity ...Phase
Interventional
-
A Phase 1/1b Study of ASP2138 in Participants With Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma or Metastatic Pancreatic Adenocarcinoma Whose Tumors Have Claudin (CLDN) 18.2 Expression
Claudin 18.2 protein, or CLDN18.2 is a protein found on cells in the digestive system. It is also found on some tumors. Researchers ...Phase
Interventional
